L-Dopa — NCD 132 | CMS Coverage Update

TL;DR: The Centers for Medicare & Medicaid Services modified NCD 132, its L-Dopa (levodopa) coverage policy, effective March 7, 2026. Here's what billing teams need to do.

NCD 132 is the National Coverage Determination governing Medicare coverage of L-Dopa (levodopa) therapy for Parkinsonism, including inpatient hospital services, skilled nursing facility stays, physical therapy, and associated laboratory tests. This policy does not list specific CPT or HCPCS codes — but it governs reimbursement across three benefit categories: diagnostic laboratory tests, inpatient hospital services, and outpatient physical therapy services. If your facility bills Medicare for any of these services in connection with L-Dopa therapy, this coverage policy applies to you.

---

Quick-Reference Table

Field	Detail Copy
Payer	CMS (Centers for Medicare & Medicaid Services)
Policy	L-Dopa — NCD 132
Policy Code	NCD 132
Change Type	Modified
Effective Date	2026-03-07
Impact Level	Medium
Specialties Affected	Neurology, Physical Therapy, SNF/Long-Term Care, Clinical Laboratory, Inpatient Hospital Billing
Key Action	Audit your documentation practices for L-Dopa-related inpatient stays, lab orders, and PT services to confirm medical necessity is clearly established in the medical record before March 7, 2026

---

CMS L-Dopa Coverage Criteria and Medical Necessity Requirements 2026

The CMS L-Dopa coverage policy under NCD 132 Medicare establishes coverage across three distinct service types. Each has its own medical necessity rules. Getting one wrong can trigger a claim denial — and the criteria are specific enough that vague documentation won't cut it.

Inpatient Hospital Services (Part A)

Inpatient hospital services for L-Dopa therapy are covered when medically required. The policy is direct: not every Parkinson's patient starting L-Dopa needs to be hospitalized. CMS draws a clear line.

A typical, well-functioning, ambulatory Parkinsonian patient with no concurrent disease does not meet medical necessity for inpatient admission at L-Dopa therapy initiation. Hospitalization is reasonable for patients with concurrent cardiovascular, gastrointestinal, or neuropsychiatric conditions. Document the concurrent disease clearly — that's what justifies the stay.

Length of stay matters here. Most patients require under two weeks. CMS considers a four-week inpatient stay reasonable in some cases, but reviewers will want to see the clinical justification. Don't let your physicians use "Parkinson's, starting L-Dopa" as a standalone admission reason. That's a denial waiting to happen.

For a drug to be an allowable inpatient hospital cost under Part A, it must meet the §1861(t) definition — either included in recognized compendia or approved by the hospital's pharmacy and drug therapeutics (P&DT) committee. Levodopa has been favorably evaluated by A.M.A. Drug Evaluations (First Edition, 1971, the replacement compendia for "New Drugs"). Your P&DT committee documentation should reflect that.

Laboratory Tests

CMS covers specific laboratory tests in connection with L-Dopa administration regardless of whether the patient is hospitalized. The covered tests include a complete blood count, liver function tests (SGOT, SGPT, and/or alkaline phosphatase), BUN or creatinine, urinalysis, blood sugar, and electrocardiogram.

These tests are medically warranted for achieving optimal dosage and controlling side effects. Weekly intervals are reasonable in certain cases, though the policy acknowledges some physicians perform them less frequently. This is one of the more flexible parts of the policy — but "reasonable" still means you need clinical context in the record, not just a standing order.

If you're billing lab tests weekly for L-Dopa management, make sure the ordering physician has documented why that frequency is appropriate for that patient. Blanket weekly orders without clinical rationale are a medical necessity risk.

Physical Therapy

Physical therapy coverage under NCD 132 is tied directly to treatment response. If L-Dopa reduces a patient's rigidity to the point where a restorative goal becomes achievable, physical therapy services required to reach that goal are covered — provided they require the skills of a qualified physical therapist and are furnished by or under that therapist's supervision.

Here's the critical cutoff: once the patient reaches their restoration potential, maintenance services do not generally require a qualified physical therapist's skills. CMS distinguishes between evaluative PT services (covered) and the execution of a maintenance program by others (not covered). A therapist can design the maintenance program and evaluate ongoing needs — but billing for the actual maintenance exercise sessions as skilled PT will get you denied.

This is a distinction that catches a lot of billing teams off guard. The therapist's evaluation and program design are payable. The aide carrying out the daily program is not a skilled PT service under this policy.

Skilled Nursing Facility (SNF) Coverage — Part A

CMS explicitly covers initiation of L-Dopa therapy in the SNF setting. The same guidelines apply as for inpatient hospital initiation — patient selection criteria, physical therapy rules, and laboratory test coverage all carry over directly.

For SNF stays where inpatient care is required for L-Dopa initiation, the policy limits the stay appropriately (the full policy text governs the exact parameters). Apply the same medical necessity scrutiny here that you would for inpatient hospital admissions.

---

CMS L-Dopa Exclusions and Non-Covered Indications

The policy is explicit on what falls outside covered services.

Maintenance physical therapy — meaning the ongoing execution of a maintenance exercise program by support staff — is not covered as skilled PT. CMS's position is that once restoration potential has been achieved, the patient no longer needs skilled therapy services to continue. The therapist's role shifts to evaluation and program design, not treatment delivery.

Inpatient hospitalization for the typical, ambulatory Parkinson's patient without concurrent disease is not covered at L-Dopa initiation. If there's no cardiovascular, gastrointestinal, or neuropsychiatric comorbidity documented, the admission doesn't meet the standard.

Lab tests ordered without connection to L-Dopa dosage optimization or side effect management fall outside the policy's coverage rationale. Frequency and clinical context have to be defensible.

---

Coverage Indications at a Glance

---

CMS L-Dopa Billing Guidelines and Action Items 2026

This is where the policy gets practical. The effective date of March 7, 2026 means you need to act now. Here's what your billing team and clinical documentation staff need to do.

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for L-Dopa Therapy Under NCD 132

The policy data for NCD 132 does not list specific CPT, HCPCS, or ICD-10 codes. This is common for older NCDs that predate CMS's current code-level documentation standards.

Your billing team should apply NCD 132 criteria to the relevant codes you're already using for inpatient hospital services, laboratory tests, and outpatient physical therapy — and document medical necessity against the criteria above. If you're uncertain how this applies to your specific code mix, consult your Medicare Administrative Contractor (MAC) for guidance on local coverage determinations that may supplement NCD 132 in your region.

This is also a situation where your compliance officer or billing consultant should weigh in. Without CMS-specified codes, MAC-level interpretation can vary — and a local coverage determination may impose additional criteria on top of the NCD.

---